Gene therapy

Cell and gene therapy concept
#CSL Behring #Drug discovery #Gene therapy #Haemophilia

Gene therapy landmark in haemophilia B

Following the news that the first patients in Denmark with haemophilia B had been treated with Hemgenix (etranacogene dezaparvovec) gene therapy since European Commission approval, DDW’s Megan Thomas spoke with Dr Fredrik Sjöö, Head of Medical Affairs in the Nordic Region at CSL Behring, as well as Radovan Tomic, Global Market Access Director… Read More

#Exclusive Content

#ALS #Arbor Biotechnologies #CNS #Financing #Gene therapy

Gene editing company announces $73.9m Series C financing

Arbor Biotechnologies has announced the closing of a $73.9 million Series C financing to support the advancement of its pipeline of novel gene editing therapeutics targeting diseases in the liver and central nervous system (CNS).   The proceeds will support clinical development of the company’s lead therapeutic candidate, ABO-101, in primary… Read More

#Business & Investment #News

DNA vector
#Gene editing #Gene therapy #iECURE #Phase II trial

Study indicates gene editing could restore OTC enzyme activity

Gene editing company iECURE has shared data from the ongoing OTC-HOPE Phase I/II study of ECUR-506, which suggest partial restoration of functional ornithine transcarbamylase (OTC) enzyme activity in the first patient dosed.  “Long-term restoration of ornithine transcarbamylase activity has the potential to allow infants afflicted with neonatal… Read More

#News #Trending News

#AAV #Clinical trials #Eye health #Gene therapy #Stargardt disease

First patient dosed in gene therapy study for Stargardt disease

SpliceBio has dosed the first patient in the Phase I/II ASTRA study of SB-007, a dual adeno-associated viral (AAV) vector, for the treatment of Stargardt disease. Stargardt disease is an inherited retinal disorder caused by mutations in the ABCA4 gene. It is the most common form of juvenile macular degeneration,… Read More

#News

Gene editing
#Base editing #Beam Therapeutics #Clinical trial #Gene editing #Gene therapy #mRNA

First clinical genetic correction of a disease-causing mutation reported

Biotechnology company Beam Therapeutics says initial data from its Phase I/II trial establish clinical proof-of-concept for BEAM-302 as a potential treatment for alpha-1 antitrypsin deficiency (AATD) and for in vivo base editing.  Preliminary results from the first three single-ascending dose cohorts demonstrated that BEAM-302 was… Read More

#Editor's Choice #News

#Bluebird Bio #Cell and gene therapy #Gene therapy #Genetic diseases #Mergers and acquisitions

New DDW Highlights podcast: 4 March 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. It’s been a mixed bag of news for gene therapies this week, ranging from… Read More

#News

#Bluebird Bio #Cell and gene therapy #Gene therapy #Genetic diseases #Mergers and acquisitions

This week in drug discovery (24-28 February) 

News round-up for 23-28 February by DDW Senior Digital Content Editor Diana Spencer. It’s been a mixed bag of news for gene therapies this week, ranging from huge successes in treating sight impairment, cystic fibrosis and hearing loss, to the quick sale of a previously successful gene therapy… Read More

#News

A child with a cochlear implant
#Gene therapy #Genetic diseases #Hearing Loss #Paediatrics #Regeneron Pharmaceuticals

Latest DB-OTO results confirm hearing improvements

Regeneron Pharmaceuticals has revealed updated data for the investigational gene therapy DB-OTO from the Phase I/II CHORD trial in 12 children who have profound genetic hearing loss due to variants of the otoferlin (OTOF) gene.   These include 72-week results showing speech and development progress… Read More

#Editor's Choice #News

Child with cystic fibrosis on ventilator
#Boehringer Ingelheim #Cystic fibrosis #Gene therapy #Imperial College London #Phase II trial

Inhaled gene therapy for cystic fibrosis enters the clinic

Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) and OXB have announced the start of LENTICLAIR 1, a Phase I/II trial of gene therapy BI 3720931.  The therapy has been designed to improve disease outcomes in people with cystic fibrosis (CF), regardless of gene… Read More

#News

Child having an eye test
#Gene therapy #Genetic diseases #MeiraGTx #Ophthalmology #UCL

Gene therapy treats rare genetic sight impairment in the UK

Four young children have gained improvements in their vision following treatment with a new genetic medicine through Moorfields Eye Hospital and UCL Institute of Ophthalmology, with the support of MeiraGTx.  The children were born with a severe impairment to their sight due to a rare genetic deficiency… Read More

#News #Trending News

bluebird bio
#Gene therapy #Genetic diseases #Mergers and acquisitions

bluebird bio agrees to acquisition due to “financial challenges”

bluebird bio has entered into a definitive agreement to be acquired by global investment firms Carlyle and SK Capital Partners in collaboration with a team of highly experienced biotech executives.  The decision was made after a third and final denial by the Food & Drug Administration (FDA) of bluebird’s appeal… Read More

#Business & Investment #News #Trending News

Genetic engineering concept
#AskBio #FDA #Gene therapy #Neuroscience #Parkinson's

Further FDA support for Parkinson’s gene therapy

AskBio’s investigational gene therapy AB-1005 for the treatment of Parkinson’s disease (PD) has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the US Food and Drug Administration (FDA).  The FDA decision follows a review of information and data provided by AskBio, including clinical evidence from the open label Phase… Read More

#News #Regulatory

Hepatitis B
#Gene editing #Gene therapy #HBV #hepatitis #Phase I trial #Precision BioSciences

Positive early clinical signs for HBV gene editing therapy

Precision BioSciences has announced positive initial results from the first administration of PBGENE-HBV in cohort 1, the lowest dose level of the ELIMINATE-B trial.   The ELIMINATE-B trial is designed to investigate PBGENE-HBV at multiple ascending dose levels with three dose administrations per dose level… Read More

#Editor's Choice #News

Gene therapy
#Asklepios BioPharmaceutical #Gene therapy #Heart failure #Phase II trial

First European participant in heart failure gene therapy trial

AskBio announced that the first participant has been randomised in Europe in GenePHIT (Gene PHosphatase Inhibition Therapy), a Phase II clinical trial of AB-1002 for the treatment of congestive heart failure (CHF).  GenePHIT is an adaptive, double-blind, placebo-controlled, randomised, multicentre trial to evaluate the… Read More

#News

Human heart
#Cardiovascular disease #Gene therapy #Phase II trial #XyloCor Therapeutics

XyloCor financing advances one-time cardiovascular gene therapy

XyloCor Therapeutics has completed a $67.5 million Series B financing to support a Phase IIb clinical trial (EXACT‑2) of XC001 (encoberminogene rezmadenovec) in refractory angina.  The trial will use a new non‑surgical method of endocardial administration via a novel injection catheter.   The financing will also fund a Phase II trial… Read More

#Business & Investment #News

#Collaboration #Gene therapy #Lipid based nanoparticle (LNP) #Orna Therapeutics #Vertex

Vertex signs multimillion dollar deal with Orna Therapeutics

Vertex Pharmaceuticals and Orna Therapeutics have announced plans to partner on gene therapies for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).  The three-year strategic research collaboration will utilise Orna’s lipid nanoparticle (LNP) delivery solutions.  In return Orna will receive upfront payments of $65 million, including an investment in… Read More

#Business & Investment #News #Trending News